Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial

Anthracycline-induced cardiotoxicity influences treatment selection and may negatively affect clinical outcomes in lymphoma patients. While epirubicin induced cardiotoxicity less often than the same dose of doxorubicin in breast cancer, higher doses of epirubicin are required in lymphoma regimens fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Kai, Gu, Juan J., Zhang, Qunling, Liu, Xiaojian, Wang, Jiachen, Li, Xiao-qiu, Luo, Jianfeng, Hernandez, Francisco J., Fernandez, Stanley F., Czuczman, Myron S., Cao, Junning, Hong, Xiaonan, Guo, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078030/
https://www.ncbi.nlm.nih.gov/pubmed/27081036
http://dx.doi.org/10.18632/oncotarget.8685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078030/
https://www.ncbi.nlm.nih.gov/pubmed/27081036
http://dx.doi.org/10.18632/oncotarget.8685

Ejemplares similares